Management strategy for open innovation in Korean biochip industry

Due to the need to access external knowledge for new product development (NPD), open innovation has been widely used in the biochip industry. Since current resources owned by single firm do not have all the capabilities, NPD in biochip requires strong interdisciplinarity, wide diversity of technological knowledge, and integration capabilities. In the present study, management strategy for open innovation is investigated for NPD in the Korean biochip industry. Open innovation is classified in three steps: (1) switching phase about starting open innovation in the NPD initial stage; (2) implementation phase about open innovation management in the NPD middle stage; and (3) transition phase about change to close innovation in the NPD final stage. Three models for three phases are developed and then tested by carrying out surveys in the Korean biochip firms. In addition, the transition phase model is evaluated in the Korean bio-pharmaceutical firms. The switching phase model suggests that research capability and external trust are the main variables that affect switching cost, which relates to the perception of advantage of open innovation. The implementation phase model suggests that technological novelty affects degree of openness, which, in turn, relates to technological capability and firm performance. Furthermore, institutional-, environmental-, and firm characteristics affect the depth- and breadth of open innovation activity. The transition phase model suggests that knowledge connected with product innovation has an impact on the open-close transition tendency, which relates to perception of advantage of close innovation. Based on the results for three phases of open innovation, we propose the management strategy for open innovation during NPD. Therefore, based on the results of analyses of the proposed model, we can evaluate the factors that affect open innovation activity and develop an appropriate management strategy of open innovation for NPD of biochip.

[1]  Jiancheng Guan,et al.  The impact of university–industry collaboration networks on innovation in nanobiopharmaceuticals , 2013 .

[2]  R Sásik,et al.  Microarray truths and consequences. , 2004, Journal of molecular endocrinology.

[3]  C. Choi,et al.  Current status of protein chip development in terms of fabrication and application , 2003, Proteomics.

[4]  Len Jessup,et al.  How Open Innovation Affects the Drivers of Competitive Advantage , 2012 .

[5]  H. Chesbrough.  The Era of Open Innovation , 2003 .

[6]  Antonello Cammarano,et al.  Open Innovation in the Pharmaceutical Industry: An Empirical Analysis on Context Features, Internal R&D, and Financial Performances , 2015, IEEE Transactions on Engineering Management.

[7]  A. Salter,et al.  The paradox of openness: Appropriability, external search and collaboration , 2014 .

[8]  P. Matthyssens,et al.  A MODEL FOR ANALYZING ENTREPRENEURIAL INNOVATION IN HIGH-TECH SECTORS , 2004 .

[9]  Stephen Roper,et al.  Internal Versus External R&D: A Study of R&D Choice with Sample Selection , 2002 .

[10]  Allen M. Weiss,et al.  Converting from Independent to Employee Salesforces: The Role of Perceived Switching Costs , 1992 .

[11]  Claudiano Sales Araujo,et al.  Open innovation and technology development process: the gap on partnership adoption from a case study perspective , 2011 .

[12]  R. Kitney,et al.  PARTNERSHIP AND INNOVATION IN THE LIFE SCIENCES , 2007 .

[13]  B. Kedia,et al.  R&D Partnership Portfolio Strategies for Breakthrough Innovation: Developing Knowledge Exchange Capabilities , 2014 .

[14]  A. B. Magalhães.  Open Innovation in the Pharmaceutical Industry , 2014 .

[15]  Mohan V. Tatikonda,et al.  Integrating Operations and Marketing Perspectives of Product Innovation: The Influence of Organizational Process Factors and Capabilities on Development Performance , 2001 .

[16]  J. Tidd.  Why We Need a Tighter Theory and More Critical Research on Open Innovation , 2013 .

[17]  D. Sjödin,et al.  Open Innovation and the Stage-Gate Process: A Revised Model for New Product Development , 2010 .

[18]  D. Gann,et al.  How open is innovation , 2010 .

[19]  Oliver Gassmann,et al.  Models for open innovation in the pharmaceutical industry. , 2013, Drug discovery today.

[20]  Tim Lenoir,et al.  The emergence and diffusion of DNA microarray technology , 2006, Journal of biomedical discovery and collaboration.

[21]  David F. Larcker,et al.  Structural Equation Models with Unobservable Variables and Measurement Error: Algebra and Statistics: , 1981 .

[22]  E. Vaara.  Strategic Alliances as Social Facts: Business, Biotechnology and Intellectual History , 2004 .

[23]  A. Link,et al.  An economic analysis of cooperative research , 1987 .

[24]  J. C. F. D. Arroyabe,et al.  The choice of partners in R&D cooperation: An empirical analysis of Spanish firms , 2008 .

[25]  Shankar Ganesan.  Determinants of Long-Term Orientation in Buyer-Seller Relationships , 1994 .

[26]  K. Eisenhardt,et al.  Resource-based View of Strategic Alliance Formation: Strategic and Social Effects in Entrepreneurial Firms , 1996 .

[27]  Lan-Ying Huang,et al.  Consumer electronics acceptance based on innovation attributes and switching costs: The case of e-book readers , 2012, Electron. Commer. Res. Appl..

[28]  Nigel Slack,et al.  Operations management , 1994 .

[29]  Markus C. Becker,et al.  A project–based perspective on complex product development , 2014 .

[30]  Priit Vahter,et al.  Learning from openness: The dynamics of breadth in external innovation linkages , 2014 .

[31]  Dirk Voelkel,et al.  Managing Open Innovation in Biotechnology , 2006 .

[32]  Koen Frenken,et al.  Branching innovation, recombinant innovation, and endogenous technological transitions , 2012 .

[33]  H. Chesbrough.  Managing Open Innovation , 2004 .

[34]  Ramon Casadesus-Masanell,et al.  Open Versus Closed Innovation: A Model of Discovery and Divergence , 2010 .

[35]  J. Swan,et al.  Trust and inter-organizational networking , 2000 .

[36]  Brian Squire,et al.  A CONTINGENT PERSPECTIVE OF OPEN INNOVATION IN NEW PRODUCT DEVELOPMENT PROJECTS , 2010 .

[37]  Richard P. Gabriel,et al.  Innovation Happens Elsewhere , 2005 .

[38]  Mohan V. Tatikonda,et al.  Technology novelty, project complexity, and product development project execution success: a deeper look at task uncertainty in product innovation , 2000, IEEE Trans. Engineering Management.

[39]  Sebastian Lohse,et al.  The Open Innovation Model , 2014 .

[40]  Vikram Nanda,et al.  Client Discretion, Switching Costs, and Financial Innovation , 2000 .

[41]  M. Dodgson,et al.  The Role of Technology in the Shift Towards Open Innovation: The Case of Procter & Gamble , 2006 .

[42]  J. Hoheisel.  Microarray technology: beyond transcript profiling and genotype analysis , 2006, Nature Reviews Microbiology.

[43]  Chih-Wen Wu,et al.  The study of service innovation for digiservice on loyalty , 2014 .

[44]  G. Ramsay.  DNA chips: State-of-the art , 1998, Nature Biotechnology.

[45]  이광호,et al.  개방형 혁신의 산업별 특성과 시사점(Open innovation) Theory, practices, and policy implications , 2008 .

[46]  G. O'Connor,et al.  The human side of radical innovation , 2004 .

[47]  Nicholas Economides,et al.  Linux vs. Windows: A Comparison of Application and Platform Innovation Incentives for Open Source and Proprietary Software Platforms , 2005 .

[48]  S. Stead,et al.  The development of marine biotechnology in Oman: Potential for capacity building through open innovation , 2015 .

[49]  Mario Kafouros,et al.  The role of open innovation in emerging economies: Do companies profit from the scientific knowledge of others? , 2012 .

[50]  Edwin R. Stafford.  Using co-operative strategies to make alliances work , 1994 .

[51]  P. Trott,et al.  Innovation risks of outsourcing in pharmaceutical new product development , 2012 .

[52]  J. West,et al.  Managing Distributed Innovation: Strategic Utilization of Open and User Innovation , 2012 .

[53]  Dale Goodhue,et al.  Develop Long-Term Competitiveness through IT Assets , 1996 .

[54]  Bing-Sheng Teng,et al.  Alliance Constellations: A Social Exchange Perspective , 2002 .

[55]  Davide Chiaroni,et al.  Investigating the adoption of open innovation in the bio‐pharmaceutical industry: A framework and an empirical analysis , 2009 .

[56]  Andrew B. Hargadon,et al.  Building an innovation factory. , 2000, Harvard business review.

[57]  Fachen Wei,et al.  The Impact of Product Complexity and Heterogeneity on Online Open Innovation Practices , 2011, LISS.

[58]  Priit Vahter,et al.  Openness and Innovation Performance: Are Small Firms Different? , 2014 .

[59]  Reinhilde Veugelers,et al.  Measuring Technological Novelty with Patent-Based Indicators , 2015 .

[60]  M. Christopher.  Logistics and supply chain management , 2011 .